[Cardiology. Platelet function testing for clinicians]

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Pathology

Background:

• Platelet P2Y12 receptor inhibition is vital for preventing ischemic events post-percutaneous coronary intervention (PCI).
• Antiplatelet medications such as clopidogrel, prasugrel, and ticagrelor are commonly used.
• The effectiveness of platelet inhibition varies due to clinical and genetic factors, creating a therapeutic window.

Purpose of the Study:

• To review current knowledge on platelet function tests and genetic tests related to P2Y12 receptor inhibition.
• To summarize the clinical utility of these tests in managing antiplatelet therapy.
• To discuss the balance between achieving adequate platelet inhibition and minimizing bleeding risk.

Main Methods:

• Review of existing literature on platelet function assays.
• Analysis of studies investigating genetic polymorphisms affecting P2Y12 receptor response.
• Synthesis of data on the clinical application of these tests in acute coronary syndromes and elective PCI settings.

Main Results:

• Platelet inhibition levels differ based on the specific antiplatelet drug and individual patient factors.
• Platelet function and genetic testing can provide insights into an individual's response to antiplatelet therapy.
• These tests may help guide therapeutic decisions to optimize efficacy and safety.

Conclusions:

• Platelet function and genetic testing offer valuable tools for personalizing antiplatelet therapy after PCI.
• Optimizing therapy involves navigating the therapeutic window to prevent cardiovascular events while avoiding excessive bleeding.
• Further integration of these tests into routine clinical practice is warranted.